Henry G. Bone

17.9k total citations · 5 hit papers
148 papers, 12.3k citations indexed

About

Henry G. Bone is a scholar working on Oncology, Orthopedics and Sports Medicine and Molecular Biology. According to data from OpenAlex, Henry G. Bone has authored 148 papers receiving a total of 12.3k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Oncology, 92 papers in Orthopedics and Sports Medicine and 48 papers in Molecular Biology. Recurrent topics in Henry G. Bone's work include Bone health and treatments (92 papers), Bone health and osteoporosis research (82 papers) and Bone Metabolism and Diseases (42 papers). Henry G. Bone is often cited by papers focused on Bone health and treatments (92 papers), Bone health and osteoporosis research (82 papers) and Bone Metabolism and Diseases (42 papers). Henry G. Bone collaborates with scholars based in United States, Canada and Belgium. Henry G. Bone's co-authors include Jacques P. Brown, Michael A. Bolognese, Michael R. McClung, David L. Kendler, Arthur C. Santora, Javier San Martín, Ronald Emkey, Richard P. Tonino, David Hosking and Jose Adolfo Rodriguez-Portales and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Henry G. Bone

147 papers receiving 11.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women

2004 982 citations Henry G. Bone, David Hosking et al. New England Journal of Medicine profile →
Romosozumab in Postmenopausal Women with Low Bone Mineral Density

2014 886 citations Michael R. McClung, Andreas Grauer et al. New England Journal of Medicine profile →
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

2017 662 citations Henry G. Bone, Rachel B. Wagman et al. profile →
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

2011 433 citations Henry G. Bone, Michael A. Bolognese et al. The Journal of Clinical Endocrinology & Metabolism profile →
A Simple Test for the Diagnosis of Absorptive, Resorptive and Renal Hypercalciurias

1975 348 citations Henry G. Bone et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Henry G. Bone

Since Specialization

Citations

This map shows the geographic impact of Henry G. Bone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry G. Bone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry G. Bone more than expected).

Fields of papers citing papers by Henry G. Bone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henry G. Bone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry G. Bone. The network helps show where Henry G. Bone may publish in the future.

Co-authorship network of co-authors of Henry G. Bone

This figure shows the co-authorship network connecting the top 25 collaborators of Henry G. Bone. A scholar is included among the top collaborators of Henry G. Bone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henry G. Bone. Henry G. Bone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism 2019 ·The Journal of Clinical Endocrinology & Metabolism ·Michael Mannstadt, B.L. Clarke, John P. Bilezikian, Henry G. Bone, Douglas Denham, Michael A. Levine, Munro Peacock, Jeffrey Rothman, Dolores Shoback, Mark Warren, Nelson B. Watts, Hak‐Myung Lee, Nicole Sherry, Tamara Vokes	47
2	ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis 2018 ·The Journal of Clinical Endocrinology & Metabolism ·Henry G. Bone, Felicia Cosman, Paul D. Miller, Gregory C. Williams, Gary Hattersley, Ming‐yi Hu, Lorraine A. Fitzpatrick, Bruce Mitlak, Socrates E. Papapoulos, René Rizzoli, Robin K. Dore, John P. Bilezikian, Kenneth G. Saag	129
3	TEN YEARS OF DENOSUMAB (DMAB) TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FREEDOM EXTENSION TRIAL 2016 ·Open Repository and Bibliography (University of Liège) ·Henry G. Bone, Maria Luisa Brandi, Jacques P. Brown, Roland Chapurlat, Steven R. Cummings, E. J. Czerwiński, Astrid Fahrleitner‐Pammer, (unknown), Kurt Lippuner, Jean‐Yves Reginster, (unknown), (unknown), (unknown), Paula Dakin, (unknown), Socrates E. Papapoulos	1
4	A Randomized Double-Blind Study of Denosumab Compared with Zoledronic Acid in Postmenopausal Women with Osteoporosis Previously Treated with Oral Bisphosphonate 2015 ·VBN Forskningsportal (Aalborg Universitet) ·Paul D. Miller, Nicola Pannacciulli, Jacques P. Brown, E. J. Czerwiński, Bettina S. Nedergaard, (unknown), Jorge Malouf, Henry G. Bone, Jean‐Yves Reginster, Andrea Singer, (unknown), (unknown), Steven R. Cummings	1
5	Romosozumab in Postmenopausal Women with Low Bone Mineral Density breakdown → 2014 ·New England Journal of Medicine ·Michael R. McClung, Andreas Grauer, Steven Boonen, Michael A. Bolognese, Jacques P. Brown, Adolfo Díez‐Pérez, Bente Langdahl, Jean‐Yves Reginster, José Zanchetta, Scott M. Wasserman, Leonid Katz, Judy Maddox, Yuching Yang, Cesar Libanati, Henry G. Bone	886
6	Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy 2013 ·Obstetrics and Gynecology ·Chris Recknor, E. J. Czerwiński, Henry G. Bone, Sydney Lou Bonnick, Neil Binkley, Santiago Palacios, Alfred H. Moffett, Suresh Siddhanti, Irene Ferreira, (unknown), Rachel B. Wagman, Jesse Hall, Michael A. Bolognese, Claude-Laurent Benhamou	110
7	Effects of Pioglitazone on Bone in Postmenopausal Women With Impaired Fasting Glucose or Impaired Glucose Tolerance: A Randomized, Double-Blind, Placebo-Controlled Study 2013 ·The Journal of Clinical Endocrinology & Metabolism ·Henry G. Bone, R. Lindsay, Michael R. McClung, Alfonso T. Perez, Marsha G. Raanan, Robert G. Spanheimer	37
8	A single-dose study of denosumab in patients with various degrees of renal impairment 2012 ·Journal of Bone and Mineral Research ·Geoffrey A. Block, Henry G. Bone, Liang Fang, Edward Lee, Desmond Padhi	244
9	Safety observations from denosumab long-term extension and cross-over studies in postmenopausal women with osteoporosis 2011 ·Open Repository and Bibliography (University of Liège) ·Henry G. Bone, R. Chapurlat, Cesar Libanati, Maria Luisa Brandi, Jacques P. Brown, E. J. Czerwiński, M. A. Krieg, Man Zhang, Dan Mellström, S. Radominski, Jean‐Yves Reginster, Heinrich Resch, Jose Andrés Román Ivorra, (unknown), Nadia Daizadeh, Andreas Grauer, Steven R. Cummings, Socrates E. Papapoulos	3
10	A phase 3 study of the efficacy and safety of Denosumab in men with low bone mineral density : design of the ADAMO 2011 ·Open Repository and Bibliography (University of Liège) ·Eric Orwoll, (unknown), Bente Langdahl, R. Chapurlat, E. J. Czerwiński, (unknown), Jean‐Yves Reginster, Alan Kivitz, (unknown), (unknown), Michael A. Bolognese, Henry G. Bone, Östen Ljunggren, Bo Abrahamsen, (unknown), Andreas Grauer, Cesar Libanati, Jesse Hall, Steven Boonen	1
11	FIVE-YEAR DENOSUMAB TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FIRST TWO YEARS OF THE FREEDOM TRIAL EXTENSION 2011 ·Data Archiving and Networked Services (DANS) ·Socrates E. Papapoulos, Z. Man, Dan Mellström, S. Radominski, Jean‐Yves Reginster, Heinrich Resch, (unknown), Camille Roux, S. R. Cummings, Henry G. Bone, Roland Chapurlat, Maria Luisa Brandi, Jacques P. Brown, E. J. Czerwiński, Nadia Daizadeh, Andreas Grauer, (unknown), Cesar Libanati	9
12	Long-term denosumab treatment of postmenopausal women with osteoporosis: results from the first year extension study of the FREEDOM trial 2010 ·Open Repository and Bibliography (University of Liège) ·R. Chapurlat, Socrates E. Papapoulos, Henry G. Bone, Maria Luisa Brandi, Jacques P. Brown, E. J. Czerwiński, Nadia Daizadeh, Andreas Grauer, Christine Haller, Marc-Antoine Krieg, Cesar Libanati, Z. Man, Dan Mellström, S. Radominski, Jean‐Yves Reginster, Heinrich Resch, (unknown), Steven R. Cummings	2
13	RONACALERET, A CALCIUM-SENSING RECEPTOR ANTAGONIST, FAILS TO INCREASE BMD 2010 ·Osteoporosis International ·L. A. Fitzpatrick, C. Dabrowski, (unknown), S. E. Papapoulos, Henry G. Bone, J P Bilezikian	1
14	Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy 2009 ·Journal of Bone and Mineral Research ·David L. Kendler, Christian Roux, Claude Laurent Benhamou, Jacques P. Brown, Michael Lillestol, Suresh Siddhanti, (unknown), Javier San Martín, Henry G. Bone	322
15	Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer 2008 ·Journal of Clinical Oncology ·Georgiana K. Ellis, Henry G. Bone, Rowan T. Chlebowski, Devchand Paul, Silvana Spadafora, J. W. G. Smith, Michelle Fan, Susie Jun	342
16	Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial 2008 ·Journal of Bone and Mineral Research ·Jacques P. Brown, Richard L. Prince, Chad Deal, Robert R. Recker, Douglas P. Kiel, (unknown), Peyman Hadji, Lorenz C. Hofbauer, José María Álvaro‐Gracia, Huei Wang, Matthew Austin, Rachel B. Wagman, Richard Newmark, Cesar Libanati, Javier San Martín, Henry G. Bone	436
17	Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis 2007 ·Annals of Internal Medicine ·Susan L. Greenspan, Henry G. Bone, Mark P. Ettinger, David A. Hanley, Robert S. Lindsay, José Zanchetta, Consuelo Blosch, Annette Mathisen, Stephen Morris, Thomas B. Marriott	291
18	A cross-sectional study of bone turnover markers in healthy premenopausal women 2007 ·Bone ·Anne E. de Papp, Henry G. Bone, Michael P. Caulfield, Risa Kagan, (unknown), Erluo Chen, Elizabeth Rosenberg, Richard E. Reitz	83
19	Ten Years’ Experience With Alendronate for Osteoporosis in Postmenopausal Women 2004 ·Obstetrical & Gynecological Survey ·Henry G. Bone, David Hosking, Jean‐Pierre Devogelaer, Joseph Tucci, Ronald Emkey, Richard P. Tonino, Jose Adolfo Rodriguez-Portales, Robert W. Downs, Jayanti Gupta, Arthur C. Santora, (unknown)	48
20	Increased circulating 1α,25 dihydroxyvitamin D3 in patients with primary hyperparathyroidism 1975 ·Clinical research ·Mark R. Haussler, (unknown), Henry G. Bone, C. Y. C. Pak	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact